Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STN1013800 in Chinese Patients With Acquired Blepharoptosis
NCT06683651Phase 3Recruiting
- Sponsor
- Santen Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in blepharoptosis comparing STN1013800 ophthalmic solution with Placebo (2 arms). Primary endpoint: Mean change from Baseline in the STN1013800 group versus the Vehicle (Placebo) group. Started Oct 2024; status: recruiting.
02
Drugs
oxymetazoline
03
Conditions
blepharoptosis
Beyond the preview
Go deeper on NCT06683651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06683651.